Bevacizumab in the treatment of HER2-negative breast cancer

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 813-821

  Lorusso, Vito ^a  

^a VITO FAZZI HOSPITAL   (Italy)

Author keywords

Bevacizumab; Breast cancer; HER2; HER2 negative breast cancer

Indexed keywords

EID: 77953503685     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3515     Document Type: Review

References (40)

1. Avastin (bevacizumab) for intravenous use [package insert]. 2006. San Francisco, Calif. Genentech Inc., April.
2. Bocci G, Nicolaou KC, Kerbel RS. 2002. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res, 62:6938-43.
3. Borgstrom P, Gold DP, Hillan KJ, et al. 1999. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res, 19:4203-14.
4. Burstein HJ, Parker LM, Savoie J, et al. 2002. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat, 76(Suppl 1):S115.
5. Burstein HJ, Spigel D, Kindsvogel K, et al. 2005. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 4).
6. Cobleigh MA, Langmuir VK, Sledge GW, et al. 2003. A phase I/II doseescalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol, 30(5 Suppl 16):117-24.
7. Colleoni M, Rocca A, Sandri MT, et al. 2002. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13:73-80.
8. Cortés-Funes H. 2007. Present and future roles of bevacizumab in breast cancer. Breast Cancer Res, 9(Suppl 1):S22.
9. D'Adamo DR, Anderson SE, Albritton K, et al. 2005. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol, 23:7135-42.
10. Dellapasqua S, Bertolini F, Bagnardi V, et al. 2008. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol, 26: in press. ecog. dfci. harvard. edu/general/ videos/etpages/e5103. html.
11. Emmenegger U, Kerbel RS. 2007. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie, 30:606-8.
12. European Medicines Agency. Avastin 25 mg/mL: summary of product characteristics [online]. URL: http:ww.emea.europa.eu/humandocs/ Humans/EPAR/avastin/avastin.htm.
13. Ferrara N, Davis-Smith T. 1997. The biology of vascular endothelial growth factor. Endocr Rev, 18:4-25.
14. Gasparini G, Longo R, Fanelli M, et al. 2005. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol, 23:1295-311.
15. Genentech Inc. Avastin™ (bevacizumab): prescribing information [online]. URL: http://www.gene.com.
16. Gennari A, Conte P, Rosso R, et al. 2005. Survival of metastatic breast carcinoma patients over a 20 year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer, 104:1742-50.
17. Gordon MS, Margolin K, Talpaz M, et al. 2001. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol, 19:843-50.
18. Higgins B, Kolinsky K, Linn M, et al. 2007. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res, 27:2279-87. http://clinicaltrials.gov/ct2/show/NCT00203372?termrTORITB02&rankB1.
19. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307:58-62.
20. Kakeji Y, Teicher BA. 1997. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs, 15:39-48.
21. Karp JE, Gojo I, Pili R, et al. 2004. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res, 10:3577-85.
22. Kerbel RS, Kamen BA. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4:423-36.
23. Kusaka M, Sudo K, Matsutani E, et al. 1994. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470(AGM-1470). Br J Cancer, 69:212-6.
24. Langmuir VK, Cobleigh MA, Herbst RS, et al. 2002. Successful long-term therapy with bevacizumab (Avastin™) in solid tumors. Proc Am Soc Clin Oncol, 1:9a. (Abstr 32).
25. Manley PW, Martiny-Baron G, Schlaeppi JM, et al. 2002. Therapies directed at vascular endothelial growth factor. Expert Opin Invest Drugs, 11:1715-36.
26. Margolin K, Gordon MS, Holmgren E, et al. 2001. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol, 19:851-6.
27. Midgley R, Kerr D. 2005. Bevacizumab-current status and future directions. Ann Oncol, 16:999-1004.
28. Miles D, Chan A, Romieu G, et al. 2008. Randomized, double blind, placebo controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC) AVADO. J Clin Oncol, (May 20 Suppl): abstr LBA1011.
29. Miller KD, Chap LI, Holmes FA, et al. 2005. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol, 23:792-9.
30. Miller K, Gradishar W, Moish C, et al. 2006. Capecitabine plus bevacizumab in first line metastatic breast cancer: an interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. Breast Cancer Res Treat, 100(Suppl 1):S103 (Abstract 2068).
31. Miller KD, O'Neill A, Perez EA, et al. 2007. Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Breast Cancer Res Treat, 106(Suppl 1):S147 (Abstract 3063).
32. Miller KD, Wang, M, Gralow J, et al. 2007. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357.2666-76.
33. Muramaki M, Miyake H, Hara I, Kamidono S. 2005. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. Int J Oncol, 26:623-8.
34. O'Shaughnessy JA, Brufsky AM. 2008. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer, 8:370-3.
35. Polichemothearpy for Early Breast Cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. 1998. Lancet, 352:930-42.
36. Relf M, LeJeune S, Scott PA, et al. 1997. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res, 57:963-9.
37. Schneider BP, Wang M, Radovich M et al. 2008. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol, 26:4672-8.
38. Slamon DJ, Romond EH, Perez EA. 2006. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol, 4(Suppl 1):4-9.
39. Sweeney CJ, Miller KD, Sissons SE et al. 2001. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res, 61:3369-72.
40. Wedam SB, Low JA, Yang SX, et al. 2006. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol, 24:769-77.